recombinant cd5l protein (MedChemExpress)
Structured Review

Recombinant Cd5l Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+cd5l+protein/pmc13013844-333-10-13?v=MedChemExpress
Average 94 stars, based on 1 article reviews
Images
1) Product Images from "Combined proteomics and metabolomics analyses revealed molecular signatures associated with proliferative diabetic retinopathy"
Article Title: Combined proteomics and metabolomics analyses revealed molecular signatures associated with proliferative diabetic retinopathy
Journal: Scientific Reports
doi: 10.1038/s41598-026-40551-1
Figure Legend Snippet: ELISA quantification of CD5L ( A ), CLU ( B ), and SERPINF1 ( C ) protein levels in the vitreous humor of DR and Control patients. * p < 0.05, **** p < 0.0001.
Techniques Used: Enzyme-linked Immunosorbent Assay, Control
Figure Legend Snippet: Immunohistochemical analysis of CD5L, CLU, and SERPINF1 expression. Immunohistochemical analysis of CD5L, CLU, and SERPINF1 expression in whole-retinal and retinal nerve fiber layer from DR and control SD rats. Images were acquired at 40×magnification, full-field view; scale bar, 25 μm. Nuclei are counterstained blue, and positive staining for CD5L, CLU, and SERPINF1 appears brown. ** p < 0.01, *** p < 0.001.
Techniques Used: Immunohistochemical staining, Expressing, Control, Staining
Figure Legend Snippet: Prediction of Transcription factors (TFs) and modification sites in key proteins. ( A ) Transcription factor prediction of key proteins. ( B ) Prediction results of PTM sites of key protein APLP2. ( C ) Prediction results of PTM sites of key protein RBP3. ( D ) Prediction results of PTM sites of key protein SERPINF1. ( E ) Prediction results of acetylation of key protein CLU. ( F ) Prediction results of acetylation of key protein PSAP. ( G ) Prediction results of phosphorylation, acetylation, ubiquitination of key protein C5. ( H ) Prediction results of key protein CD5L.
Techniques Used: Modification, Phospho-proteomics, Ubiquitin Proteomics
Figure Legend Snippet: Prediction of drug candidates targeting key proteins and functional effects of exogenous CD5L on endothelial cells. ( A ) Molecular docking diagram of key protein RBP3 and drug VITAMIN A PALMITATE. ( B ) Molecular docking diagram of key protein RBP3 and drug VITAMIN A PALMITATE. The purple is the key protein, the iridescent is the drug, and the yellow dotted line is the hydrogen bond between the two, as well as the corresponding bond length and residue. ( C ) EdU assay showing the effect of CD5L on C166 cell proliferation.(Images are shown at 10×magnification, scale bar, 2 μm, proliferating cells are indicated by green fluorescence (EdU), ** p <0.01). ( D ) Scratch wound assay showing the effect of CD5L on C166 cell migration (* p <0.05).
Techniques Used: Functional Assay, Residue, EdU Assay, Fluorescence, Scratch Wound Assay Assay, Migration

![The Gas6–Axl–LXRα/β signaling pathway inhibits NLRP3 inflammasome activation in BMDMs by promoting <t>AIM</t> production. ELISA was performed to quantify the abundance of IL-1β (A, E, H, K) and IL-18 (B, F, I, L) in culture supernatants of bone marrow-derived macrophages (BMDMs). (C, G, J, M) Caspase-1 activity was measured in culture supernatants of BMDMs. (D) Left: Representative immunofluorescence confocal microscopic images of ASC specks (green). Arrows point to ASC specks. Original magnification: 200 ×. Scale bars: 50 μm. Right: Quantification of the percentage of cells with ASC specks (4 × 200 cells/nuclei [DAPI-stained], analyzed with ImageJ). BMDMs were transfected with two types of siRNAs for AIM (A–D) , LXRα (E–G) , LXRβ (H–J) , or Axl (K–M) and then treated with rGas6 (100 ng/ml) or <t>rAIM</t> (1 μg/ml) for 24 h, followed by LPS (100 ng/ml) for 4 h and ATP [1 mM in (A–C) and (E–M) or 5 mM in (D) ] for 1 h. Values represent the mean ± standard error of three (A–C) , (E–M) or four (D) independent experiments. NS, not significant; *P < 0.05, **P < 0.01, and ***P < 0.001 compared with control or as indicated.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_3840/pmc11873840/pmc11873840__fimmu-16-1523166-g003.jpg)
